Yaozh News Star Club Edu BBS TOP100 Customer Service APP
Iphone Download Android Download
  • English
  • 简体中文
Login Register
Search
Current Location： Home > Feedback Help Print

【结 构 式】

【药物名称】E-5531

【化学名称】2-Deoxy-6-O-[2-deoxy-3-O-[3(R)-[5(Z)-dodecenoyloxy]decyl]-6-O-methyl-2-(3-oxotetradecanamido)-4-O-phosphono-beta-D-glucopyranosyl]-3-O-[3(R)-hydroxydecyl]-2-(3-oxotetradecanamido)-alpha-D-glucopyranose-1-O-phosphate

【CA登记号】151663-12-6 (tetrasodium salt)

【 分 子 式 】C73H136N2O22P2

【 分 子 量 】1455.84567

【开发单位】Eisai (Originator)

【药理作用】ANTIINFECTIVE THERAPY, Treatment of Septic Shock, TLR4 (LPS) Receptor Antagonists

合成路线1合成路线2合成路线3合成路线4合成路线5合成路线6合成路线7合成路线8

合成路线1

Peracetylation of (I) to yield (II), followed by treatment with thiophenol and boron trifluoride, afforded the mannopyranoside (III). After methanolysis of the acetate esters of (III) in the presence of NaOMe, the resultant tetrahydroxy derivative (IV) was protected as the bis-acetonide (V) by treatment with 2,2-dimethoxypropane and 10-camphorsulfonic acid. The phenylsulfanyl group of (V) was reductively removed by means of lithium and a catalytic amount of naphthalene, yielding the dihydropyran derivative (VI). The free hydroxyl group of (VI) was then esterified with Ac2O in pyridine to give (VII). Addition of sodium azide to dihydropyran (VII) in the presence of cerium ammonium nitrate furnished the azido nitrate (VIII). The nitrate ester of (VIII) was then selectively cleaved by means of sodium nitrite, giving alcohol (IX), which was further protected by silylation with tert-butyldimethylsilyl chloride and imidazole to provide silyl ether (X). Subsequent alcoholysis of the acetate ester group of (X) in the presence of NaOMe provided the key intermediate (XI).

参考文献 中间体
【1】 Christ, W.J.; Kawata, T.; Hawkins, L.D.; Kobayashi, S.; Asano, O.; Rossignol, D.P. (Eisai Co., Ltd.); Anti-endotoxin cpds.. EP 0536969; JP 1993194470; US 5530113 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 43107 (3S,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetrol 3458-28-4 C6H12O6 详情 详情
(II) 54319 [(2R,3R,4S,5S,6R)-3,4,5,6-tetrakis(acetyloxy)tetrahydro-2H-pyran-2-yl]methyl acetate n/a C16H22O11 详情 详情
(III) 59072 (2R,3S,4S,5S)-3,5-bis(acetyloxy)-2-[(acetyloxy)methyl]-6-(phenylsulfanyl)tetrahydro-2H-pyran-4-yl acetate C20H24O9S 详情 详情
(IV) 59073 (2R,3S,4S,5S)-2-(hydroxymethyl)-6-(phenylsulfanyl)tetrahydro-2H-pyran-3,4,5-triol C12H16O5S 详情 详情
(V) 59074 (3aS,4S,5aR,9aS,9bR)-2,2,8,8-tetramethyl-4-(phenylsulfanyl)hexahydro[1,3]dioxolo[4',5':4,5]pyrano[3,2-d][1,3]dioxine; (3aS,4S,5aR,9aS,9bR)-2,2,8,8-tetramethylhexahydro[1,3]dioxolo[4',5':4,5]pyrano[3,2-d][1,3]dioxin-4-yl phenyl sulfide C18H24O5S 详情 详情
(VI) 59075 (4aR,8R,8aS)-2,2-dimethyl-4,4a,8,8a-tetrahydropyrano[3,2-d][1,3]dioxin-8-ol C9H14O4 详情 详情
(VII) 59076 (4aR,8R,8aR)-2,2-dimethyl-4,4a,8,8a-tetrahydropyrano[3,2-d][1,3]dioxin-8-yl acetate C11H16O5 详情 详情
(VIII) 59077 (4aR,7R,8R,8aR)-7-azido-2,2-dimethyl-6-(nitrooxy)hexahydropyrano[3,2-d][1,3]dioxin-8-yl acetate C11H16N4O8 详情 详情
(IX) 59078 (4aR,7R,8R,8aR)-7-azido-6-hydroxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl acetate C11H17N3O6 详情 详情
(X) 59079 (4aR,6S,7R,8R,8aR)-7-azido-6-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl acetate C17H31N3O6Si 详情 详情
(XI) 59080 (4aR,6S,7R,8R,8aS)-7-azido-6-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-ol C15H29N3O5Si 详情 详情

合成路线2

Reformatskii condensation of the organozinc reagent derived from methyl bromoacetate (XIII) with n-heptyl cyanide (XII) gave rise to the keto ester adduct (XIV). Catalytic hydrogenation of (XIV) in the presence of the chiral catalyst generated from dichloro(cycloocta-1,5-diene)ruthenium and (R)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl furnished the (R)-hydroxyester (XV) in high enantiomeric excess. Ester group reduction in (XV) by means of LiAlH4 afforded diol (XVI), which was further converted to the primary tosylate (XVII) with p-toluenesulfonyl chloride in pyridine. Then, alkylation of the intermediate alcohol (XI) with tosylate (XVII) under Williamson's ether synthesis conditions provided the common precursor (XVIII).

参考文献 中间体
【1】 Christ, W.J.; Kawata, T.; Hawkins, L.D.; Kobayashi, S.; Asano, O.; Rossignol, D.P. (Eisai Co., Ltd.); Anti-endotoxin cpds.. EP 0536969; JP 1993194470; US 5530113 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(XI) 59080 (4aR,6S,7R,8R,8aS)-7-azido-6-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-ol C15H29N3O5Si 详情 详情
(XII) 59081 octanenitrile 124-12-9 C8H15N 详情 详情
(XIII) 12309 methyl 2-bromoacetate; methyl bromoacetate 96-32-2 C3H5BrO2 详情 详情
(XIV) 59082 methyl 3-oxodecanoate C11H20O3 详情 详情
(XV) 59083 methyl (3R)-3-hydroxydecanoate C11H22O3 详情 详情
(XVI) 59084 (3R)-1,3-decanediol C10H22O2 详情 详情
(XVII) 49121 (3R)-3-hydroxydecyl 4-methylbenzenesulfonate C17H28O4S 详情 详情
(XVIII) 59085 (3R)-1-[((4aR,6S,7R,8R,8aS)-7-azido-6-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl)oxy]-3-decanol C25H49N3O6Si 详情 详情

合成路线3

Protection of the free hydroxyl of (XVIII) as the allyloxycarbonyl derivative (XIX) was achieved by sequential treatment with phosgene and then with allyl alcohol. Acetonide group hydrolysis in (XIX) under acidic conditions gave diol (XX), which was selectively silylated at the primary hydroxyl group with tert-butyldimethylsilyl chloride and imidazole to afford (XXI). The remaining hydroxyl group of (XXI) was subsequently protected as the allyl carbonate (XXII) with phosgene and allyl alcohol as above. Then, regioselective mono-desilylation of (XXII) with HF provided the desired building block (XXIII).

参考文献 中间体
【1】 Christ, W.J.; Kawata, T.; Hawkins, L.D.; Kobayashi, S.; Asano, O.; Rossignol, D.P. (Eisai Co., Ltd.); Anti-endotoxin cpds.. EP 0536969; JP 1993194470; US 5530113 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(XVIII) 59085 (3R)-1-[((4aR,6S,7R,8R,8aS)-7-azido-6-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl)oxy]-3-decanol C25H49N3O6Si 详情 详情
(XIX) 59086 (1R)-1-{2-[((4aR,6S,7R,8R,8aS)-7-azido-6-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl)oxy]ethyl}octyl allyl carbonate C29H53N3O8Si 详情 详情
(XX) 59087 allyl (1R)-1-(2-{[(2S,3R,4R,5S,6R)-3-azido-2-{[tert-butyl(dimethyl)silyl]oxy}-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl carbonate C26H49N3O8Si 详情 详情
(XXI) 59088 allyl (1R)-1-(2-{[(2S,3R,4R,5S,6R)-3-azido-2-{[tert-butyl(dimethyl)silyl]oxy}-6-({[tert-butyl(dimethyl)silyl]oxy}methyl)-5-hydroxytetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl carbonate C32H63N3O8Si2 详情 详情
(XXII) 59089 allyl (1R)-1-(2-{[(2R,3S,4R,5R,6S)-3-{[(allyloxy)carbonyl]oxy}-5-azido-6-{[tert-butyl(dimethyl)silyl]oxy}-2-({[tert-butyl(dimethyl)silyl]oxy}methyl)tetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl carbonate C36H67N3O10Si2 详情 详情
(XXIII) 59009 N-(1-adamantyl)-N-methylamine; N-methyl-1-adamantanamine C11H19N 详情 详情

合成路线4

The precursor cis-dodec-5-enoic acid (XXIX) was prepared as shown in Scheme 4. The lithium acetylide of 1-octyne (XXIV) was alkylated with 1,3-diiodopropane (XXV) to give the iodoalkyne (XXVI). Displacement of the iodide of (XXVI) with KCN in hot DMSO provided nitrile (XXVII), which was hydrolyzed to the corresponding carboxylic acid (XXVIII) employing KOH in ethylene glycol at 140 C. Partial hydrogenation of the triple bond in the presence of poisoned Lindlar catalyst furnished the (Z)-olefin (XXIX).

参考文献 中间体
【1】 Christ, W.J.; Kawata, T.; Hawkins, L.D.; Kobayashi, S.; Asano, O.; Rossignol, D.P. (Eisai Co., Ltd.); Anti-endotoxin cpds.. EP 0536969; JP 1993194470; US 5530113 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(XXIV) 59091 1-octyne C8H14 详情 详情
(XXV) 42364 1,3-diiodopropane 627-31-6 C3H6I2 详情 详情
(XXVI) 59092 1-iodo-4-undecyne C11H19I 详情 详情
(XXVII) 59093 5-dodecynenitrile C12H19N 详情 详情
(XXVIII) 59094 5-dodecynoic acid C12H20O2 详情 详情
(XXIX) 49124 (Z)-5-dodecenoic acid C12H22O2 详情 详情

合成路线5

The common precursor (XVIII) was converted into building block (XXXV) as follows. Esterification of (XVIII) with the unsaturated fatty acid (XXIX) by means of DCC and DMAP gave ester (XXX). The acetonide group of (XXX) was then hydrolyzed to diol (XXXI) under acidic conditions. Methylation of (XXXI) with iodomethane in the presence of silver oxide produced a mixture of two regioisomeric methyl ethers. In this mixture, the undesired 4-methoxy compound (XXXIII) was then selectively silylated at the free primary 6-hydroxyl group, which allowed chromatographic separation from the target 6-methoxy compound (XXXII). Phosphitylation of (XXXII), followed by oxidation of the intermediate phosphite with m-chloroperbenzoic acid, furnished phosphate (XXXIV). Desilylation of (XXXIV) to the required intermediate (XXXV) was accomplished by treatment with HF in acetonitrile.

参考文献 中间体
【1】 Christ, W.J.; Kawata, T.; Hawkins, L.D.; Kobayashi, S.; Asano, O.; Rossignol, D.P. (Eisai Co., Ltd.); Anti-endotoxin cpds.. EP 0536969; JP 1993194470; US 5530113 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(XVIII) 59085 (3R)-1-[((4aR,6S,7R,8R,8aS)-7-azido-6-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl)oxy]-3-decanol C25H49N3O6Si 详情 详情
(XXIX) 49124 (Z)-5-dodecenoic acid C12H22O2 详情 详情
(XXX) 59095 (1R)-1-{2-[((4aR,6S,7R,8R,8aS)-7-azido-6-{[tert-butyl(dimethyl)silyl]oxy}-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl)oxy]ethyl}octyl (Z)-5-dodecenoate C37H69N3O7Si 详情 详情
(XXXI) 59096 (1R)-1-(2-{[(2S,3R,4R,5S,6R)-3-azido-2-{[tert-butyl(dimethyl)silyl]oxy}-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl (Z)-5-dodecenoate C34H65N3O7Si 详情 详情
(XXXII) 59097 (1R)-1-(2-{[(2S,3R,4R,5S,6R)-3-azido-2-{[tert-butyl(dimethyl)silyl]oxy}-5-hydroxy-6-(methoxymethyl)tetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl (Z)-5-dodecenoate C35H67N3O7Si 详情 详情
(XXXIII) 59098 (1R)-1-(2-{[(2S,3R,4R,5S,6R)-3-azido-2-{[tert-butyl(dimethyl)silyl]oxy}-6-({[tert-butyl(diphenyl)silyl]oxy}methyl)-5-methoxytetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl (Z)-5-dodecenoate C51H85N3O7Si2 详情 详情
(XXXIV) 59099 (1R)-1-(2-{[(2S,3R,4R,5S,6R)-3-azido-5-{[bis(allyloxy)phosphoryl]oxy}-2-{[tert-butyl(dimethyl)silyl]oxy}-6-(methoxymethyl)tetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl (Z)-5-dodecenoate C41H76N3O10PSi 详情 详情
(XXXV) 59100 (1R)-1-(2-{[(3R,4R,5S,6R)-3-azido-5-{[bis(allyloxy)phosphoryl]oxy}-2-hydroxy-6-(methoxymethyl)tetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl (Z)-5-dodecenoate C35H62N3O10P 详情 详情

合成路线6

The hydroxyl group of (XXXV) was activated by treatment with trichloroacetonitrile to produce the corresponding trichloroacetimidate (XXXVI) as a diastereomeric mixture, which was used without separation. Coupling between imidates (XXXVI) and building block (XXIII) was accomplished by means of trimethylsilyl triflate, producing the disaccharide derivative (XXXVII). The azido groups of (XXXVII) were then reduced employing tin(II)tris-benzenethiolate triethylamine complex to afford diamine (XXXVIII).

参考文献 中间体
【1】 Christ, W.J.; Kawata, T.; Hawkins, L.D.; Kobayashi, S.; Asano, O.; Rossignol, D.P. (Eisai Co., Ltd.); Anti-endotoxin cpds.. EP 0536969; JP 1993194470; US 5530113 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(XXXVIa) 59101 (1R)-1-[2-({(2S,3R,4R,5S,6R)-3-azido-5-{[bis(allyloxy)phosphoryl]oxy}-6-(methoxymethyl)-2-[(2,2,2-trichloroethanimidoyl)oxy]tetrahydro-2H-pyran-4-yl}oxy)ethyl]octyl (Z)-5-dodecenoate C37H62Cl3N4O10P 详情 详情
(XXXVIb) 59102 (1R)-1-[2-({(2R,3R,4R,5S,6R)-3-azido-5-{[bis(allyloxy)phosphoryl]oxy}-6-(methoxymethyl)-2-[(2,2,2-trichloroethanimidoyl)oxy]tetrahydro-2H-pyran-4-yl}oxy)ethyl]octyl (Z)-5-dodecenoate C37H62Cl3N4O10P 详情 详情
(XXIII) 59090 allyl (1R)-1-(2-{[(2R,3S,4R,5R,6S)-3-{[(allyloxy)carbonyl]oxy}-5-azido-6-{[tert-butyl(dimethyl)silyl]oxy}-2-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl carbonate C30H53N3O10Si 详情 详情
(XXXV) 59100 (1R)-1-(2-{[(3R,4R,5S,6R)-3-azido-5-{[bis(allyloxy)phosphoryl]oxy}-2-hydroxy-6-(methoxymethyl)tetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl (Z)-5-dodecenoate C35H62N3O10P 详情 详情
(XXXVII) 59103 (1R)-1-(2-{[(2R,3R,4R,5S,6R)-2-[((2R,3S,4R,5R,6S)-3-{[(allyloxy)carbonyl]oxy}-4-[((3R)-3-{[(allyloxy)carbonyl]oxy}decyl)oxy]-5-azido-6-{[tert-butyl(dimethyl)silyl]oxy}tetrahydro-2H-pyran-2-yl)methoxy]-3-azido-5-{[bis(allyloxy)phosphoryl]oxy}-6-(methoxymethyl)tetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl (Z)-5-dodecenoate C65H113N6O19PSi 详情 详情
(XXXVIII) 59104 (1R)-1-(2-{[(2R,3R,4R,5S,6R)-2-[((2R,3S,4R,5R,6S)-3-{[(allyloxy)carbonyl]oxy}-4-[((3R)-3-{[(allyloxy)carbonyl]oxy}decyl)oxy]-5-amino-6-{[tert-butyl(dimethyl)silyl]oxy}tetrahydro-2H-pyran-2-yl)methoxy]-3-amino-5-{[bis(allyloxy)phosphoryl]oxy}-6-(methoxymethyl)tetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl (Z)-5-dodecenoate C65H117N2O19PSi 详情 详情

合成路线7

Keto ester (XLI) was obtained by Reformatskii condensation of the organozinc reagent generated from benzyl bromoacetate (XL) with n-undecyl cyanide (XXXIX). Subsequent hydrogenolysis of the benzyl ester of (XLI) in the presence of Pearlman's catalyst furnished keto acid (XLII). Acylation of the diamino compound (XXXVIII) with ketoacid (XLII), by means of DCC, provided diamide (XLIII). Then, desilylation of (XLIII) to afford alcohol (XLIV) was accomplished employing HF in acetonitrile.

参考文献 中间体
【1】 Christ, W.J.; Kawata, T.; Hawkins, L.D.; Kobayashi, S.; Asano, O.; Rossignol, D.P. (Eisai Co., Ltd.); Anti-endotoxin cpds.. EP 0536969; JP 1993194470; US 5530113 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(XXXVIII) 59104 (1R)-1-(2-{[(2R,3R,4R,5S,6R)-2-[((2R,3S,4R,5R,6S)-3-{[(allyloxy)carbonyl]oxy}-4-[((3R)-3-{[(allyloxy)carbonyl]oxy}decyl)oxy]-5-amino-6-{[tert-butyl(dimethyl)silyl]oxy}tetrahydro-2H-pyran-2-yl)methoxy]-3-amino-5-{[bis(allyloxy)phosphoryl]oxy}-6-(methoxymethyl)tetrahydro-2H-pyran-4-yl]oxy}ethyl)octyl (Z)-5-dodecenoate C65H117N2O19PSi 详情 详情
(XXXIX) 59105 lauronitrile C12H23N 详情 详情
(XL) 12869 benzyl 2-bromoacetate 5437-45-6 C9H9BrO2 详情 详情
(XLI) 59106 benzyl 3-oxotetradecanoate C21H32O3 详情 详情
(XLII) 59107 3-oxotetradecanoic acid C14H26O3 详情 详情
(XLIII) 59108 (1R)-1-[2-({(2R,3R,4R,5S,6R)-2-({(2R,3S,4R,5R,6S)-3-{[(allyloxy)carbonyl]oxy}-4-[((3R)-3-{[(allyloxy)carbonyl]oxy}decyl)oxy]-6-{[tert-butyl(dimethyl)silyl]oxy}-5-[(3-oxotetradecanoyl)amino]tetrahydro-2H-pyran-2-yl}methoxy)-5-{[bis(allyloxy)phosphoryl]oxy}-6-(methoxymethyl)-3-[(3-oxotetradecanoyl)amino]tetrahydro-2H-pyran-4-yl}oxy)ethyl]octyl (Z)-5-dodecenoate C93H165N2O23PSi 详情 详情
(XLIV) 59109 (1R)-1-[2-({(2R,3R,4R,5S,6R)-2-({(2R,3S,4R,5R)-3-{[(allyloxy)carbonyl]oxy}-4-[((3R)-3-{[(allyloxy)carbonyl]oxy}decyl)oxy]-6-hydroxy-5-[(3-oxotetradecanoyl)amino]tetrahydro-2H-pyran-2-yl}methoxy)-5-{[bis(allyloxy)phosphoryl]oxy}-6-(methoxymethyl)-3-[(3-oxotetradecanoyl)amino]tetrahydro-2H-pyran-4-yl}oxy)ethyl]octyl (Z)-5-dodecenoate C87H151N2O23P 详情 详情

合成路线8

Alcohol (XLIV) was phosphorylated by treatment with diallyl N,N-diisopropylphosphoramidite, followed by oxidation with m-chloroperbenzoic acid, to furnish the diphosphate derivative (XLV). Finally, the allyl phosphate esters and allyloxycarbonyl protecting groups of (XLV) were simultaneously removed by treatment with tetrakis(triphenylphosphine)palladium to yield the title compound.

参考文献 中间体
【1】 Christ, W.J.; Kawata, T.; Hawkins, L.D.; Kobayashi, S.; Asano, O.; Rossignol, D.P. (Eisai Co., Ltd.); Anti-endotoxin cpds.. EP 0536969; JP 1993194470; US 5530113 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(XLIV) 59109 (1R)-1-[2-({(2R,3R,4R,5S,6R)-2-({(2R,3S,4R,5R)-3-{[(allyloxy)carbonyl]oxy}-4-[((3R)-3-{[(allyloxy)carbonyl]oxy}decyl)oxy]-6-hydroxy-5-[(3-oxotetradecanoyl)amino]tetrahydro-2H-pyran-2-yl}methoxy)-5-{[bis(allyloxy)phosphoryl]oxy}-6-(methoxymethyl)-3-[(3-oxotetradecanoyl)amino]tetrahydro-2H-pyran-4-yl}oxy)ethyl]octyl (Z)-5-dodecenoate C87H151N2O23P 详情 详情
(XLV) 59110 (1R)-1-[2-({(2R,3R,4R,5S,6R)-2-({(2R,3S,4R,5R,6R)-3-{[(allyloxy)carbonyl]oxy}-4-[((3R)-3-{[(allyloxy)carbonyl]oxy}decyl)oxy]-6-{[bis(allyloxy)phosphoryl]oxy}-5-[(3-oxotetradecanoyl)amino]tetrahydro-2H-pyran-2-yl}methoxy)-5-{[bis(allyloxy)phosphoryl]oxy}-6-(methoxymethyl)-3-[(3-oxotetradecanoyl)amino]tetrahydro-2H-pyran-4-yl}oxy)ethyl]octyl (Z)-5-dodecenoate C93H160N2O26P2 详情 详情
Extended Information